Theragnostics
Updated: March 15, 2026
CEO - Manfred Rüdiger
Country: UK | Add Funding
Theragnostics develops fluorine-18 based radiopharmaceuticals. THG-008, the startup’s lead drug, is a fluorine-18 radiolabelled poly-ADP-ribose polymerase (PARP) inhibitor (rPARPi). It aids in head and neck cancer, as well as brain cancer imaging.
Theragnostics develops fluorine-18 based radiopharmaceuticals. THG-008, the startup’s lead drug, is a fluorine-18 radiolabelled poly-ADP-ribose polymerase (PARP) inhibitor (rPARPi). It aids in head and neck cancer, as well as brain cancer imaging.
